PowderClinical Overview
Indacaterol (110mcg) and Glycopyrronium (50mcg Powder for Inhalation) is a dual-bronchodilator combination (LABA + LAMA) on the WHO Model List framework. Indacaterol relaxes airway smooth muscle by stimulating beta-2 adrenergic receptors; glycopyrronium competitively blocks muscarinic M3 receptors on bronchial smooth muscle, inhibiting acetylcholine-mediated bronchoconstriction. Combining two distinct bronchodilator mechanisms delivers superior lung function improvement (FEV1), dyspnea reduction, and exacerbation prevention compared to either monotherapy. Indicated for once-daily maintenance bronchodilator treatment of Chronic Obstructive Pulmonary Disease (COPD).
Active Pharmaceutical Ingredients
Verified Clinical References
Usage Guidelines
Inhale the dry powder contents of 1 capsule once daily at the same time each day using the Breezhaler device. Do NOT swallow capsules. Not indicated for asthma.
General Administration Advice: Adhere strictly to the prescribed dosage, frequency, and treatment course. For oral medications, swallow with sufficient water. Never stop antibiotics, psychiatric medications, or antihypertensives abruptly without clinical direction.
Possible Side Effects
Common: Upper respiratory tract infection, dry mouth, nasopharyngitis, dizziness, musculoskeletal pain, cough. Rare/Severe: Paradoxical bronchospasm, worsening of urinary retention (in BPH), narrow-angle glaucoma attack, and atrial fibrillation.
*Note: Individual physiological responses vary. While many patients experience few or no side effects, notify your treating physician if adverse reactions persist or if hypersensitivity (angioedema, skin rash, dyspnea) occurs.
Precautions & Warnings
Indicated for COPD only, NOT for asthma. Caution in patients with prostatic hyperplasia, urinary retention, or narrow-angle glaucoma. Do not use more than 1 capsule daily.
Medical Disclaimer: Statutory Clinical Disclaimer: The information provided is for educational and price-transparency purposes only and does not constitute medical advice, pulmonological diagnosis, or respiratory management recommendations. Inhalation therapies and allergy medications should be used strictly under the guidance of a qualified pulmonologist or registered medical practitioner.
Indacaterol 150mcg + Mometasone Furoate 160mcg Powder for Inhalation
Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.
Indacaterol 150mcg + Mometasone Furoate 320mcg Powder for Inhalation
Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.
Indacaterol 150mcg + Mometasone Furoate 80mcg Powder for Inhalation
Indacaterol (150mcg) and Mometasone Furoate (80mcg/160mcg/320mcg Powder for Inhalation) is an advanced once-daily LABA and inhaled corticosteroid combination. Indacaterol is an ultra-long-acting beta-2 agonist (ultra-LABA) providing 24-hour bronchodilator coverage from a single dose; mometasone furoate provides powerful glucocorticoid anti-inflammatory action with negligible systemic oral bioavailability (<1%). Indicated for once-daily maintenance treatment of asthma in adults and adolescents inadequately controlled with ICS/LABA combinations.